Analysis: a percentage that describes a very small base

More than 100% growth is accurate and it is also a statement about $105,000 becoming $241,000. At this stage of a device launch, percentage growth carries almost no information about the eventual size of the business; the useful numbers are the ones underneath it. Two of those stand out.

The first is gross margin. Cost of revenues of $884 against revenue of $241 in the quarter means each system sold cost multiples of what it fetched. The company explains part of the gap as an accounting artefact, since pre-clearance manufacturing costs were already expensed through research and development and so did not burden first-quarter cost of revenues, which lowers the first-quarter cost of revenues and raises the second-quarter figure. But it also names higher manufacturing labour costs and increased customer concessions, and concessions are a price signal, not an accounting one. Whether they persist as the sales force expands from 8 to 12 territories is the more informative question than the growth rate.

The second is the shape of the spending. Sales, general and administrative expense more than doubled year on year in the quarter while research and development fell. That is a company converting from a development organisation into a commercial one, which is the correct sequence after a 510(k) clearance, but it front-loads fixed cost against revenue measured in hundreds of thousands of dollars. With $67.3 million of working capital and $10,042 of cash used in six months of operations, the funding position is comfortable for now, and the constraint is time rather than solvency.

The Israeli clearance and the Lovell agreement are options rather than revenue. Federal healthcare purchasing runs on long qualification cycles, and a distribution agreement with an intermediary is not an order. A reader would look for three things in the next filing: revenue in the third quarter against the $241,000 of the second, whether cost of revenues falls below revenue as volumes rise, and whether the territory count reaches the stated 12 without a further step up in sales expense.

What the documents say

Microbot Medical Inc. (Nasdaq: MBOT) said on July 7, 2026 that revenue and new customer numbers for the second quarter each grew by more than 100% against the first quarter, the first full quarter after it moved its LIBERTY Endovascular Robotic System from a limited market release to a full market release. The company repeated the claim in a Form 8-K filed the same day, in a single sentence under Item 8.01.

The quarterly report filed on August 11 puts numbers behind the percentage. Revenue was $105,000 in the three months to March 31, 2026 and $241,000 in the three months to June 30, 2026, and $346,000 for the half. Those are the amounts a doubling describes.

What the company reported

Microbot, based in Hingham, Massachusetts, with operations in Israel, sells one product. Revenue in both the quarter and the half came exclusively from sales of the LIBERTY system to hospital customers, against no revenue at all in the corresponding periods of 2025, when the company had not begun commercial operations.

The company named the second quarter’s commercial developments. Health systems in Massachusetts, North Carolina, Michigan and Pennsylvania adopted the system. Sites that had taken LIBERTY during the limited market release increased procedure volume in the second quarter compared with the first, which the company attributes to site expansion and more users moving to the system. Sales coverage went from 4 to 8 territories during the quarter, with a stated plan to reach 12 across the United States by the end of the year.

Microbot also disclosed an agreement with Lovell Government Services Inc. to serve federal healthcare systems including the Veterans Health Administration, the Military Health System and the Indian Health Service; a marketing clearance from the Israeli Ministry of Health’s AMAR Division, making Israel the first country outside the United States to approve the system; and an agreement to establish a second manufacturing site.

The regulatory record behind the launch

The US clearance that made the launch possible is on the public record at the Food and Drug Administration. LIBERTY was cleared through the 510(k) pathway under number K243789, submitted by Microbot Medical Ltd. of Yokneam, Israel. The FDA received the submission on 2024-12-09 and issued a decision of substantially equivalent on 2025-09-04. The device is listed as a steerable catheter control system, product code DXX, regulation number 870.1290, class 2, reviewed by the cardiovascular advisory committee.

That date matters to the accounts. The company states it began ramping up inventory manufacturing for units intended for sale after receiving FDA clearance on September 4, 2025, and that manufacturing costs incurred before clearance had been expensed within research and development rather than capitalised into inventory.

What the second quarter cost

Revenue grew, and so did the cost of producing it. Cost of revenues, reported in thousands, was $884 in the second quarter and $987 for the half, against revenues of $241 and $346. The company says cost of revenues rose from the first quarter to the second primarily because certain units sold in the first quarter carried inventory manufactured before FDA clearance, the cost of which had already gone through research and development in earlier periods, and because of higher manufacturing labour costs and increased customer concessions in the second quarter. It expects cost per system to fall as production volumes grow and says cost-reduction initiatives are under way.

Operating expenses moved in opposite directions. Research and development expense, net of government grants, fell to $1,861 in the quarter from $2,111, and to $3,154 for the half from $3,570, mainly because of higher grant recognition and the capitalisation of manufacturing costs into inventory. Sales, general and administrative expense rose to $3,684 from $1,612 in the quarter, and to $6,713 from $3,174 for the half, on hiring of sales and marketing staff, salary increases and legal and operating costs tied to commercialisation.

Net loss for the quarter was $5,627 against $3,500 a year earlier, and $9,298 for the half against $6,101, offset in part by financing income of $561 in the quarter and $1,210 in the half from short-term investments. Operations used $10,042 of cash in the half against $5,447 a year earlier.

The balance sheet is the reason none of that is immediately pressing. Net working capital was approximately $67.3 million at June 30, 2026, consisting primarily of cash, cash equivalents and marketable securities, down from approximately $76.4 million at December 31, 2025. Since inception in November 2010 the company has raised approximately $168.3 million and accumulated a total loss of approximately $113.4 million.